Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
November 20, 2015
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Daniel V T Catenacci, Wei-Li Liao, Lei Zhao, et al.
Annals of Surgical Oncology
|
January 6, 2022
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels
Ankit Dhiman, Charles C Vining, Hunter D D Witmer, et al.
The Oncologist
|
February 25, 2014
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing
Jeffrey S Ross, Kai Wang, Laurie Gay, et al.
The Lancet. Oncology
|
September 30, 2017
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 13, 2015
Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution
Shaoping Ling, Zheng Hu, Zuyu Yang, et al.
The Lancet. Oncology
|
October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V T Catenacci, Melissa R Junttila, Theodore Karrison, et al.
Cancer Biology & Therapy
|
May 6, 2011
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
Daniel V T Catenacci, Gustavo Cervantes, Soheil Yala, et al.
Cancer Discovery
|
November 25, 2020
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Daniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, et al.
Tumori
|
June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
Maria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
November 20, 2015
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Daniel V T Catenacci, Wei-Li Liao, Lei Zhao, et al.
Annals of Surgical Oncology
|
January 6, 2022
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels
Ankit Dhiman, Charles C Vining, Hunter D D Witmer, et al.
The Oncologist
|
February 25, 2014
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing
Jeffrey S Ross, Kai Wang, Laurie Gay, et al.
The Lancet. Oncology
|
September 30, 2017
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 13, 2015
Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution
Shaoping Ling, Zheng Hu, Zuyu Yang, et al.
The Lancet. Oncology
|
October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V T Catenacci, Melissa R Junttila, Theodore Karrison, et al.
Cancer Biology & Therapy
|
May 6, 2011
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
Daniel V T Catenacci, Gustavo Cervantes, Soheil Yala, et al.
Cancer Discovery
|
November 25, 2020
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Daniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, et al.
Tumori
|
June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
Maria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Page
of 7